US RE50,497 E1
(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Brandon H. Brown, Burlingame, CA (US); Ernest A. Carra, Foster City, CA (US); Jeffrey N. Hemenway, San Mateo, CA (US); Henry Morrison, Dublin, CA (US); Troy Reynolds, San Francisco, CA (US); Bing Shi, Redwood City, CA (US); Dimitrios Stefanidis, Mountain View, CA (US); Fang Wang, Foster City, CA (US); Matthew Robert Warr, Madison, CT (US); James Andrew Whitney, Guilford, CT (US); and Yan Xin, San Carlos, CA (US)
Assigned to GlaxoSmithKline LLC, Wilmington, DE (US)
Filed by GlaxoSmithKline LLC, Wilmington, DE (US)
Filed on Jan. 25, 2023, as Appl. No. 18/159,328.
Application 18/159,328 is a continuation of application No. 17/013,342, filed on Sep. 4, 2020, granted, now RE49445, issued on Mar. 7, 2023.
Application 17/013,342 is a continuation of application No. 16/164,681, filed on Oct. 18, 2018, granted, now RE48285, issued on Oct. 27, 2020.
Application 16/164,681 is a reissue of application No. 14/736,690, filed on Jun. 11, 2015, granted, now 9,469,613, issued on Oct. 18, 2016.
Application 18/159,328 is a reissue of application No. 14/736,690, filed on Jun. 11, 2015, granted, now 9,469,613, issued on Oct. 18, 2016.
Claims priority of provisional application 62/011,315, filed on Jun. 12, 2014.
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/42 (2006.01); A61K 31/535 (2006.01); A61K 31/5377 (2006.01); C07D 265/30 (2006.01)
CPC C07D 239/42 (2013.01) [A61K 31/535 (2013.01); A61K 31/5377 (2013.01); C07D 265/30 (2013.01); C07B 2200/13 (2013.01)] 24 Claims
 
[ 24. A pharmaceutical composition comprising:
a compound (i) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II;
a compound (ii) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl) benzamide dihydrochloride monohydrate Form II, wherein one or more hydrogen atoms attached to a carbon atom of the compound are replaced by a deuterium atom; and
a pharmaceutically acceptable excipient.]